AIMS: To examine the influence of a pharmaceutical care programme on disease control and health-related quality of life in Type 2 diabetes patients in the United Arab Emirates. METHODS:A total of 240 Type 2 diabetes patients were recruited into a randomized, controlled, prospective clinical trial with a 12-month follow-up. A range of clinical measures, medication adherence and health-related quality of life (Short Form 36) were evaluated at baseline and up to 12 months. Intervention group patients received pharmaceutical care from a clinical pharmacist, whereas control group patients received their usual care from medical and nursing staff. The primary outcome measure was change in HbA(1c). British National Formulary and Framingham scoring methods were used to estimate changes in 10-year coronary heart disease risk scores in all patients. RESULTS: A total of 234 patients completed the study. Significant reductions (P < 0.001) in mean values (baseline vs. 12 months; 95% confidence interval) of HbA(1c)[8.5% (8.3, 8.7) vs. 6.9% (6.7, 7.1)], systolic [131.4 mmHg (128.1, 134.7) vs. 127.2 mmHg (124.4, 130.1)] and diastolic blood pressure [85.2 mmHg (83.5, 86.8) vs. 76.3 mmHg (74.9, 77.7)] were observed in the intervention group; no significant changes were noted in the control group. The mean Framingham risk prediction score in the intervention group was 10.56% (9.7, 11.4) at baseline; this decreased to 7.7% (6.9, 8.5) (P < 0.001) at 12 months but remained unchanged in the control group. CONCLUSIONS: The pharmaceutical care programme resulted in better glycaemic control and reduced cardiovascular risk scores in Type 2 diabetes patients over a 12-month period.
RCT Entities:
AIMS: To examine the influence of a pharmaceutical care programme on disease control and health-related quality of life in Type 2 diabetespatients in the United Arab Emirates. METHODS: A total of 240 Type 2 diabetespatients were recruited into a randomized, controlled, prospective clinical trial with a 12-month follow-up. A range of clinical measures, medication adherence and health-related quality of life (Short Form 36) were evaluated at baseline and up to 12 months. Intervention group patients received pharmaceutical care from a clinical pharmacist, whereas control group patients received their usual care from medical and nursing staff. The primary outcome measure was change in HbA(1c). British National Formulary and Framingham scoring methods were used to estimate changes in 10-year coronary heart disease risk scores in all patients. RESULTS: A total of 234 patients completed the study. Significant reductions (P < 0.001) in mean values (baseline vs. 12 months; 95% confidence interval) of HbA(1c)[8.5% (8.3, 8.7) vs. 6.9% (6.7, 7.1)], systolic [131.4 mmHg (128.1, 134.7) vs. 127.2 mmHg (124.4, 130.1)] and diastolic blood pressure [85.2 mmHg (83.5, 86.8) vs. 76.3 mmHg (74.9, 77.7)] were observed in the intervention group; no significant changes were noted in the control group. The mean Framingham risk prediction score in the intervention group was 10.56% (9.7, 11.4) at baseline; this decreased to 7.7% (6.9, 8.5) (P < 0.001) at 12 months but remained unchanged in the control group. CONCLUSIONS: The pharmaceutical care programme resulted in better glycaemic control and reduced cardiovascular risk scores in Type 2 diabetespatients over a 12-month period.
Authors: R W Baran; K Crumlish; H Patterson; J Shaw; W G Erwin; J D Wylie; P Duong Journal: Am J Health Syst Pharm Date: 1999-08-01 Impact factor: 2.637
Authors: Normand G Boulé; S John Weisnagel; Timo A Lakka; Angelo Tremblay; Richard N Bergman; Tuomo Rankinen; Arthur S Leon; James S Skinner; Jack H Wilmore; D C Rao; Claude Bouchard Journal: Diabetes Care Date: 2005-01 Impact factor: 19.112
Authors: Hae Mi Choe; Sonya Mitrovich; Daniel Dubay; Rodney A Hayward; Sarah L Krein; Sandeep Vijan Journal: Am J Manag Care Date: 2005-04 Impact factor: 2.229
Authors: Brian K Irons; Ranee J Lenz; Stephanie L Anderson; Benita L Wharton; Butch Habeger; H Glenn Anderson Journal: Pharmacotherapy Date: 2002-10 Impact factor: 4.705
Authors: Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella Journal: Hypertension Date: 2003-12-01 Impact factor: 10.190
Authors: Salah M Aburuz; Nailya R Bulatova; Al-Moatasem M Yousef; Mutasim A Al-Ghazawi; Izzat A Alawwa; Akram Al-Saleh Journal: Int J Clin Pharm Date: 2011-03-26
Authors: Joni L Strom Williams; Rebekah J Walker; Brittany L Smalls; Jennifer A Campbell; Leonard E Egede Journal: Diabetes Manag (Lond) Date: 2014-01-01